Skip to content

Exososmes in Atrophic Scars Management

Evaluation of Intralesional Exosomes Versus Intralesional Saline in The Treatment of Atrophic Scars: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07569666
Enrollment
12
Registered
2026-05-06
Start date
2025-06-15
Completion date
2027-02-01
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Scar

Brief summary

Lay Summary (Simple Explanation) Atrophic scars are depressed scars that form when the skin does not heal properly, commonly seen after acne or injuries. These scars can affect appearance and confidence, and current treatments may not always give satisfactory results. This study aims to evaluate a new treatment using exosomes, which are tiny particles naturally released by cells that help in skin repair and regeneration. Researchers will compare the effect of injecting exosomes directly into scars versus injecting a simple saltwater solution (saline), which serves as a control. Participants will be randomly assigned to receive either exosome injections or saline injections. Neither the patient nor the evaluator may know which treatment is given, to ensure fair comparison. The goal is to determine whether exosomes can safely and effectively improve the appearance and texture of atrophic scars.

Interventions

OTHERIntralesional exosomes

exosomes are injected within the substance of the scar.

all patients will receive both, exosomes and saline, each injected into one scar.

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age \>18 years * Either gender * Scars of any duration * Multiple scars at one side or both sides of the face. * Patients are willing to sign written informed consent statements before beginning treatment.

Exclusion criteria

* Pregnant females. * Patients with one scar. * Hypersensitivity to any of the used treatments. * Patient with infection at the site of the scar. * Patients with unrealistic expectations. * Patient refusing to sign on the consent.

Design outcomes

Primary

MeasureTime frameDescription
modified Manchester Scar Scale3 months after 4 biweekly sessionsScar appearance was assessed using the Modified Manchester Scar Scale. The Modified Manchester Scar Scale ranges from 4 to 24, with lower scores indicating better scar appearance and higher scores indicating worse scar appearance

Secondary

MeasureTime frameDescription
Scar thickness measurement in millimetres by Ultrasound examination3 months after 4 biweekly sessionsScar characteristics, including scar thickness and echogenicity, will be assessed using high-frequency ultrasound examination. Scar thickness will be measured in millimeters, and changes from baseline to follow-up will be summarized. Higher scar thickness values indicate greater scar tissue thickness

Countries

Egypt

Contacts

CONTACTmona Elradi
monaelradi@medicine.zu.edu.eg+201067070550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026